Isocitrate dehydrogenase inhibitor‐driven differentiation may resemble secondary graft failure in post‐allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia

Rasche, Adrianne; Mason, Emily F.; Strickland, Stephen A.; Byrne, Michael; Ferrell, P. Brent

doi:10.1111/bjh.17573

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differentiation syndrome has emerged as a potential adverse event with an incidence of 19% [95,96]. In the post-HCT setting, this effect can mirror secondary graft failure [97]. Two prospective trials are underway investigating the enasidenib and ivosidenib maintenance (Table 3) [98].…”

Section: Isocitrate Dehydrogenase Inhibitorsmentioning

confidence: 99%

Detecting and preventing post-hematopoietic cell transplant relapse in AML

Austin

Byrne

2021

Current Opinion in Hematology

Self Cite

View full text Add to dashboard Cite

Purpose of review Relapsed disease is the primary cause of mortality for acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (HCT). This review outlines the most recent advances in the detection and prevention of AML relapse following allogeneic HCT. Recent findings Conventional methods for predicting post-HCT relapse rely on the molecular and cytogenetics features present at diagnosis. These methods are slow to reflect a growing understanding of the molecular heterogeneity of AML and impact of new therapies on post-HCT outcomes. The use of measurable residual disease (MRD) techniques, including multiparameter flow cytometry and molecular testing, may improve the prognostic ability of these models and should be incorporated into post-HCT surveillance whenever possible. In the post-HCT setting, FLT3 inhibitor maintenance data indicate that effective therapies can improve post-HCT outcomes. Maintenance data with DNA methyltransferase inhibitor monotherapy is less compelling and outcomes may improve with combinations. Early interventions directed at preemptive management of MRD may further improve post-HCT outcomes. Summary Post-HCT AML relapse prevention has evolved to include more sensitive measures of disease detection and novel therapies that may improve outcomes of poor-risk AML patients. Additional work is needed to maintain this progress.

show abstract